Online first
Artykuł przeglądowy
Opublikowany online: 2023-08-04
Wyświetlenia strony 291
Wyświetlenia/pobrania artykułu 51
Pobierz cytowanie

Eksport do Mediów Społecznościowych

Eksport do Mediów Społecznościowych

Panitumumab w leczeniu chorych na uogólnionego raka jelita grubego

Agnieszka J. Słowik1, Piotr Wysocki12

Streszczenie

Panitumumab jest ludzkim przeciwciałem monoklonalnym klasy IgG2 zarejestrowanym w terapii chorych na przerzutowego raka jelita grubego. Skuteczność leku potwierdzono podczas stosowania w skojarzeniu z chemioterapią w I linii leczenia zaawansowanego raka jelita grubego oraz w monoterapii po niepowodzeniu schematów zawierających oksaliplatynę, irynotekan oraz fluorouracyl. Warunkiem zastosowania panitumumabu jest wykluczenie obecności mutacji w eksonach 2., 3. i 4. genów KRAS i NRAS oraz mutacji aktywującej (V600E) w genie BRAF. Toksyczność jest typowa dla leków blokujących receptor naskórkowego czynnika wzrostu (EGFR, epidermal growth factor receptor) i nie stanowi czynnika ograniczającego wartość leczenia. Panitumumab ma ugruntowane miejsce w leczeniu chorych na uogólnionego raka jelita grubego z uwagi na znaczący wpływ na poprawę rokowania, korzystny profil bezpieczeństwa oraz dostępność biomarkerów predykcyjnych umożliwiających dobór chorych odnoszących korzyść z leczenia.

Artykuł dostępny w formacie PDF

Dodaj do koszyka: 49,00 PLN

Posiadasz dostęp do tego artykułu?

Referencje

  1. Morgan E, Arnold M, Gini A, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023; 72(2): 338–344.
  2. Pfeiffer P, Gruenberger T, Glynne-Jones R. Synchronous liver metastases in patients with rectal cancer: can we establish which treatment first? Ther Adv Med Oncol. 2018; 10: 1758835918787993.
  3. Wysocki P. Recent progress in the systemic treatment of colorectal cancer. Oncol Clin Pract. 2021; 17(4): 157–163.
  4. Siena S, Sartore-Bianchi A, Di Nicolantonio F, et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst. 2009; 101(19): 1308–1324.
  5. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008; 26(10): 1626–1634.
  6. Han CB, Li F, Ma JT, et al. Concordant KRAS mutations in primary and metastatic colorectal cancer tissue specimens: a meta-analysis and systematic review. Cancer Invest. 2012; 30(10): 741–747.
  7. Chen J, Zeng F, Forrester SJ, et al. Expression and Function of the Epidermal Growth Factor Receptor in Physiology and Disease. Physiol Rev. 2016; 96(3): 1025–1069.
  8. Hecht JR, Mitchell E, Neubauer MA, et al. Lack of correlation between epidermal growth factor receptor status and response to Panitumumab monotherapy in metastatic colorectal cancer. Clin Cancer Res. 2010; 16(7): 2205–2213.
  9. Wojtukiewicz MZ, Sierko E, Szambora P. Patofizjologiczne podstawy terapii ukierunkowanej na zahamowanie funkcji receptora czynnika wzrostu naskórka (EGFR). Oncol Clin Prac. 2010; 6(5): 217–227.
  10. Schneider-Merck T, Lammerts van Bueren JJ, Berger S, et al. Human IgG2 antibodies against epidermal growth factor receptor effectively trigger antibody-dependent cellular cytotoxicity but, in contrast to IgG1, only by cells of myeloid lineage. J Immunol. 2010; 184(1): 512–520.
  11. Fakih M, Vincent M. Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer. Curr Oncol. 2010; 17 Suppl 1(Suppl 1): S18–S30.
  12. Wysocki P, Kwinta Ł, Potocki P, et al. Systemic treatment of patients with solid tumors during the COVID-19 (SARS-CoV-2) pandemic — comprehensive recommendations of the Polish Society of Clinical Oncology. Oncology in Clinical Practice. 2020; 16(2): 41–51.
  13. Siena S, Cassidy J, Tabernero RL, et al. Randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as a first-line treatment in patients with metastatic colorectal cancer: the PRIME trial. Prezentacja na ASCO Gastrointestinal Cancers Symposium; 22-24 stycznia, 2010; Orlando, Floryda, Stany Zjednoczone. Abstrakt 283.
  14. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol. 2010; 28(31): 4697–4705.
  15. Douillard JY, Oliner KS, Siena S, et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med. 2013; 369(11): 1023–1034.
  16. Douillard JY, Siena S, Cassidy J, et al. Final results from PRIME: randomized phase III study of panitumumab with FOLFOX4 for first-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(7): 1346–1355.
  17. Carrato A, Abad A, Massuti B, et al. Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD). Eur J Cancer. 2017; 81: 191–202.
  18. Schwartzberg LS, Rivera F, Karthaus M, et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol. 2014; 32(21): 2240–2247.
  19. Arnold D, Lueza B, Douillard JY, et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. Ann Oncol. 2017; 28(8): 1713–1729.
  20. Yoshino T, Watanabe J, Shitara K, et al. Panitumumab (PAN) plus mFOLFOX6 versus bevacizumab (BEV) plus mFOLFOX6 as first-line treatment in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC): Results from the phase 3 PARADIGM trial. J Clin Oncol. 2022; 40(17_suppl): LBA1–LBA1.
  21. Venook AP, Niedzwiecki D, Lenz HJ, et al. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA. 2017; 317(23): 2392–2401.
  22. Geredeli C, Yasar N. FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer. World J Surg Oncol. 2018; 16(1): 67.
  23. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009; 360(14): 1408–1417.
  24. Dawoud E, Shorbagy DE, Hamza D, et al. Panitumumab plus FOLFIRI vs. Bevacizumab plus FOLFIRI for first line treatment of metastatic colorectal cancer with wild-type KRAS tumors; a retrospective study. Austral - Asian Journal of Cancer. 2014; 13(1): 5–11.
  25. Karthaus M, Hofheinz RD, Mineur L, et al. Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer. Br J Cancer. 2016; 115(10): 1215–1222.
  26. Chen Q, Cheng M, Wang Z, et al. The efficacy and safety of panitumumab plus irrinotecan-based chemotherapy in the treatment of metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 2016; 95(50): e5284.
  27. Peeters M, Price TJ, Cervantes A, et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol. 2014; 25(1): 107–116.
  28. Peeters M, Oliner KS, Price TJ, et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res. 2015; 21(24): 5469–5479.
  29. Peeters M, Forget F, Karthaus M, et al. Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with wild-type metastatic colorectal carcinoma. ESMO Open. 2018; 3(2): e000297.
  30. Munemoto Y, Nakamura M, Takahashi M, et al. SAPPHIRE: a randomised phase II study of planned discontinuation or continuous treatment of oxaliplatin after six cycles of modified FOLFOX6 plus panitumumab in patients with colorectal cancer. Eur J Cancer. 2019; 119: 158–167.
  31. Modest DP, Karthaus M, Fruehauf S, et al. Panitumumab Plus Fluorouracil and Folinic Acid Versus Fluorouracil and Folinic Acid Alone as Maintenance Therapy in Wild-Type Metastatic Colorectal Cancer: The Randomized PANAMA Trial (AIO KRK 0212). J Clin Oncol. 2022; 40(1): 72–82.
  32. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol. 2007; 25(13): 1658–1664.
  33. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004; 351(4): 337–345.
  34. Yamaguchi T, Iwasa S, Nagashima K, et al. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer. Anticancer Res. 2016; 36(7): 3531–3536.
  35. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15(6): 569–579.
  36. Taniguchi H, Yamanaka T, Sakai D, et al. Panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G. J Clin Oncol. 2018; 36(4_suppl): 745–745.
  37. Douillard JY, Siena S, Peeters M, et al. Impact of early tumour shrinkage and resection on outcomes in patients with wild-type RAS metastatic colorectal cancer. Eur J Cancer. 2015; 51(10): 1231–1242.
  38. Douillard J, Siena S, Peeters M, et al. Impact of Baseline Age on Efficacy and Safety of First-Line Panitumumab (Pmab) + Folfox4 Vs Folfox4 Treatment. Ann Oncol. 2014; 25: iv187.
  39. Asimakopoulou N, Souglakos J, Kentepozidis N, et al. Hellenic Oncology Research Group. Efficacy of panitumumab in older patients with metastatic colorectal cancer: a retrospective analysis using the database of the Hellenic Oncology Research Group (HORG). J Geriatr Oncol. 2019; 10(1): 143–148.